

Chronic Lymphocytic Leukemia

A study to look at the safety and efficacy of obinutuzumab with bendamustine in people with a type of blood cancer called ‘chronic lymphocytic leukemia’ (GIBB)

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02320487 ML29538

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG induction therapy in participants with previously untreated CLL. The anticipated time on study treatment is 24 weeks.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT02320487 ML29538
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
